Tailored study design & rapid initiation

Progress your preclinical drug candidate with speed and certainty

Gubra has extensive experience with diet-induced obese (DIO) animals and has successfully profiled numerous anti-obesity drug candidates in these translational models. Our preclinical CRO services include efficacy and mode-of-action studies on weight loss drugs, utilizing state-of-the-art in vivo, biochemical, histological and NGS technologies.

Explore our data

Download the Latest Posters

Download our recent posters and explore how we can help accelerate development of your preclinical drug candidate with conclusive data on weight loss efficacy and mode-of-action.

Distinct metabolic effects of semaglutide and resmetirom at thermoneutrality in diet-induced obese mice

Download

Renal cell-type associated therapeutic effects of semaglutide in a mouse model of hypertension accelerated diabetic kidney disease

Download

Semaglutide exerts anti-tumor action in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH with advanced fibrosis and HCC

Download

Standard Obesity & Diabetes Study Outline

Diet-Induced Obesity (DIO) Mouse Model

All study design can be customized to your specific research needs. Contact us for a free consultation to get your customized study outline, quotation as well as expert advice on how to progress your study.

Download

Explore kidney study outlines Explore MASH study outlines

“

We are experts in bridging preclinical and clinical drug development.

MARCO TOZZI Senior Scientist

Marco has a strong background within preclinical obesity and diabetes research. Reach out to Marco to get valuable scientific guidance in the design and execution of preclinical obesity/diabetes studies and how to optimally profile anti-obesity/diabetes drugs.

Have any questions?

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 2650